Community-acquiredpneumonia


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This article highlights the diagnostics and treatment of community-acquired pneumonia and using of cephalospoins of the second generation, in particular cefuroxime axetil as part of the drug of choice in the treatment of patients with community-acquired pneumonia.

Full Text

Restricted Access

About the authors

Vsevolod V. Skvortsov

Volgograd State Medical University

Email: vskvortsov1@ya.ru
Dr. of Medical sciences, Associate professor at Propaedeutic at Internal Medicine Department

Boleslav N. Levitan

Astrakhan State Medical University

Email: bolev@mail.ru
MD, professor, Head of Faculty Therapy Department

Ellina A. Golieva

Volgograd State Medical University

Email: golieva133@yandex.ru
4th year student of General Medicine Department

Georgii I. Malyakin

Volgograd State Medical University

Email: manuljke@gmail.com
4th year student of General Medicine Department

References

  1. Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med 2013; 138: 109-18.
  2. Syrjala H, Broas M, Suramo I, Ojala A, Lahde S. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 2008; 27: 358-63.
  3. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC et al. Infectious Diseases Society of America/American Thoracic Society consensus guide- lines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2017; 44 Suppl 2:S27-S72.
  4. Basi SK, Marrie TJ, Huang JQ, Majumdar SR. Patients admitted to hospital with suspected pneumonia and normal chest radiographs: epidemiology, microbiology, and outcomes. Am J Med 2014; 117: 305-11.
  5. American Thoracic Society. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
  6. Mathers C, Bernard C, and Moesgaard Iburg K. WHO. Global Burden of Disease in 2002:data sources, methods and results 2010. Ref Type: Generic.
  7. Niederman MS. Community-acquired pneumonia: the U.S. perspective. Semin Respir Crit Care Med 2009; 30: 179-88.
  8. WHO/UNICEF. Pneumonia: The forgotten killer of children. 2008. Ref Type: Generic
  9. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 2017; 336: 243-50.
  10. Агафонова О.В., Гриценко Т.А., Богданова Ю.В. и др. Поликлиническая терапия: Учебник / под ред. Д.И. Давыдкина, Ю.В. Щукина. - 2-е изд., перераб. и доп. - М.: ГЭОТАР-Медиа, 2020. - 840с. doi: 10.33029/9704-5545-6-PLT-2020-1-840.
  11. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 2016; 275: 134-41.
  12. Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. Am J Med 2014; 96: 313-20.
  13. Baik I, Curhan GC, Rimm EB, Bendich A, Willett WC, Fawzi WW. A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women. Arch Intern Med 2010; 160:3082-8.
  14. Marrie TJ. Community-acquired pneumonia in the elderly. Clin Infect Dis 2010; 31: 1066-78.
  15. Fernandez-Sabe N, Carratala J, Roson B, Dorca J, Verdaguer R, Manresa F, Gudiol F. Community-acquired pneu- monia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine (Baltimore) 2013; 82: 159-69.
  16. Jennings LC, Anderson TP, Beynon KA, Chua A, Laing RT, Werno AM et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008; 63: 42-8.
  17. Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 2008; 134: 1141-48.
  18. Hayden FG. Rhinovirus and the lower respiratory tract. Rev Med Virol 2014; 14: 17-31.
  19. Marcos MA, Esperatti M, Torres A. Viral pneumonia. Curr Opin Infect Dis 2009; 22: 143-7.
  20. Hageman JC, Uyeki TM, Francis JS, Jernigan DB, Wheeler JG, Bridges CB et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12: 894-9.
  21. Palacios G, Hornig M, Cisterna D, Savji N, Bussetti AV, Kapoor V et al. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS One 2009; 4: e8540.
  22. Murray RJ, Robinson JO, White JN, Hughes F, Coombs GW, Pearson JC et al. Community-acquired pneumonia due to pandemic A(H1N1)2009 influenzavirus and methicillin resistant Staphylococcus aureus co-infection. PLoS One 2010; 5: e8705.
  23. Goetz MB RDTA. Pyogenic bacterial pneumonia, lung abscess, and Empyema. In Mason RJ MJBVNJ, editor. Murray and Nadel’s Textbook of Respiratory Medicine. 4th edition. Philadelphia, PA: Saunders Elsevier; 2005.
  24. Menendez R, Martinez R, Reyes S, Mensa J, Filella X, Marcos MA et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009; 64: 587-91.
  25. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-82.
  26. Espana PP, Capelastegui A, Quintana JM, Soto A, Gorordo I, Garcia-Urbaneja M et al. A prediction rule to identify allocation of inpatient care in community-acquired pneumonia. Eur Respir J 2003; 21: 695-701.
  27. Liapikou A, Ferrer M, Polverino E, Balasso V, Esperatti M, Piner R et al. Severe Community-Acquired Pneumonia: Validation of the Infectious Diseases Society of America/ American Thoracic Society Guidelines to Predict an Intensive Care Unit Admission. Clin Infect Dis 2009; 48: 377-85.
  28. Визель А., Визель И., Гизатуллина Э. Пневмония у больных ХОБЛ, получающих ингаляционные глюкокортикостероиды. Врач, 2017; 2 (28): 17-23
  29. Лаврова О., Петрова М. Особенности диагностики и лечения внебольничной пневмонии у беременных. Врач, 2018; 8 (29): 8-11. https://doi.org/10.29296/25877305-2018-08-02
  30. Титова О., Кузубова Н., Склярова Д., Барышникова К., Александров А., Половников И. Особенности внебольничной пневмонии у пациентов, госпитализированных в пульмонологическое отделение. Врач, 2019; 10 (30): 43-49 https://doi.org/10.29296/25877305-2019-10-09
  31. Воробьева А., Сапожников В. Значение типа конституции для своевременной диагностики острой пневмонии у детей. Врач, 2020; 2 (31): 12-17 https://doi. org/10.29296/25877305-2020-02-03
  32. Афанасьев Н., Байда А., Батурин В. Оказание помощи больным внебольничной пневмонией в сельских стационарах ставропольского края. Врач, 2019; 3 (30): 73-75 https://doi.org/10.29296/25877305-2019-03-16
  33. Штейнер М., Биктагиров Ю., Белоусова Т. Бронхоскопия в неврологической практике. Врач, 2015; (4): 60-63
  34. Титова О., Кузубова Н., Александров А., Перлей В, Шумилов А. Особенности гемодинамики при внебольничной пневмонии на фоне ХОБЛ. Врач, 2018; 12 (29): 51-54 https://doi.org/10.29296/25877305-2018-12-12
  35. Бородулина Е., Яковлева Е. Диссеминированная форма мелкоклеточного рака легких в практике врача-пульмонолога. Врач, 2019; 4 (30): 65-69 https://doi. org/10.29296/25877305-2019-04-12

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies